Literature DB >> 18716743

Immune thrombocytopenic purpura.

V Gupta1, V Tilak, B D Bhatia.   

Abstract

Immune thrombocytopenic purpura (ITP) is the commonest cause of sudden onset thrombocytopenia in a healthy child. The condition is frequently preceded by a viral infection. The hematological parameters are essentially normal except a low platelet count. Bone marrow examination is not routinely indicated except in specific situations. The pros and cons of drug treatment have been discussed as the disease is benign with excellent prognosis in majority of the cases. The various treatment options including low and high dose steroids, intravenous immunoglobulins and anti D have been discussed at length with other modalities of treatment and role of splenectomy. Current therapeutic options with rituximab and other drugs for stimulating platelet production in chronic cases have also been included in discussion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716743     DOI: 10.1007/s12098-008-0137-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  22 in total

1.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

Authors: 
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 2.  Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood.

Authors:  Milen Minkov
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

3.  Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.

Authors:  I Warrier; J B Bussel; L Valdez; J Barbosa; D S Beardsley
Journal:  J Pediatr Hematol Oncol       Date:  1997 May-Jun       Impact factor: 1.289

4.  Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP).

Authors:  M D Carcao; A Zipursky; S Butchart; M Leaker; V S Blanchette
Journal:  Acta Paediatr Suppl       Date:  1998-06

Review 5.  Current challenges in the management of children with idiopathic thrombocytopenic purpura.

Authors:  George R Buchanan; Leah Adix
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

Review 6.  Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors.

Authors:  Massimo Franchini; Marco Zaffanello; Dino Veneri; Giuseppe Lippi
Journal:  Pediatr Blood Cancer       Date:  2007-07       Impact factor: 3.167

7.  Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.

Authors:  S Ozsoylu; T R Sayli; G Oztürk
Journal:  Pediatr Hematol Oncol       Date:  1993 Oct-Dec       Impact factor: 1.969

8.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

9.  Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Authors:  Christof Schweizer; Frederic J Reu; Anthony D Ho; Manfred Hensel
Journal:  Ann Hematol       Date:  2007-07-11       Impact factor: 3.673

Review 10.  Update on the management of immune thrombocytopenic purpura in children.

Authors:  Michael D Tarantino; Paula Hb Bolton-Maggs
Journal:  Curr Opin Hematol       Date:  2007-09       Impact factor: 3.284

View more
  1 in total

1.  Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia.

Authors:  Mohammad Ali Mashhadi; Mahmoud Ali Kaykhaei; Zahra Sepehri; Ebrahim Miri-Moghaddam
Journal:  Daru       Date:  2012-08-28       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.